## Antonella Tufano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8329321/publications.pdf

Version: 2024-02-01

69 papers 1,548 citations

304743

22

h-index

330143 37 g-index

70 all docs

70 docs citations

70 times ranked

2283 citing authors

#	Article	IF	CITATIONS
1	Spontaneous Muscle Hematoma in Patients with COVID-19: A Systematic Literature Review with Description of an Additional Case Series. Seminars in Thrombosis and Hemostasis, 2022, 48, 100-108.	2.7	21
2	Acquired Factor V Inhibitor after Coronavirus Disease 2019 (COVID-19). Seminars in Thrombosis and Hemostasis, 2022, 48, 124-126.	2.7	5
3	Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation. Journal of Clinical Medicine, 2022, 11, 915.	2.4	1
4	Comparison of Full-Dose vsÂModerate-Dose Systemic Thrombolysis for the Treatment of Patients With Acute Pulmonary Embolism. Chest, 2022, 162, 448-451.	0.8	1
5	Atrial cardiomyopathy: Pathophysiology and clinical implications. European Journal of Internal Medicine, 2022, 101, 29-31.	2.2	7
6	Systemic Catheter-Related Venous Thromboembolism in Children: Data From the Italian Registry of Pediatric Thrombosis. Frontiers in Pediatrics, 2022, 10, 843643.	1.9	7
7	Optimizing antithrombotic therapy for atrial fibrillation in cancer. Thrombosis Research, 2022, 213, S103-S106.	1.7	1
8	Sustained High D-Dimer in Outpatients Who Have Recovered from Mild to Moderate Coronavirus Disease 2019 (COVID-19). Seminars in Thrombosis and Hemostasis, 2021, , .	2.7	7
9	Cancer-Associated Splanchnic Vein Thrombosis. Seminars in Thrombosis and Hemostasis, 2021, 47, 931-941.	2.7	8
10	Clinical Differences between COVID-19 and a COVID-Like Syndrome. Journal of Clinical Medicine, 2021, 10, 2519.	2.4	6
11	The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology. Seminars in Thrombosis and Hemostasis, 2021, 47, 899-906.	2.7	6
12	The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. Viruses, 2021, 13, 1720.	3.3	9
13	Arterial Thrombosis in Cancer Patients: An Update. Seminars in Thrombosis and Hemostasis, 2021, 47, 942-949.	2.7	2
14	Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 4925.	2.4	27
15	Cardiovascular and Thromboembolic Diseases in Oncology: Novel Aspects and Revisited Issues. Seminars in Thrombosis and Hemostasis, 2021, 47, 896-898.	2.7	1
16	Cardiovascular and Thromboembolic Diseases in Oncology: Novel Aspects and Revisited Issues. Seminars in Thrombosis and Hemostasis, 2021, 47, 895-895.	2.7	0
17	Speckle tracking echocardiography in patients with systemic lupus erythematosus: A meta-analysis. European Journal of Internal Medicine, 2020, 73, 16-22.	2.2	26
18	The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians. Journal of Clinical Medicine, 2020, 9, 3379.	2.4	5

#	Article	lF	Citations
19	Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. Thrombosis Research, 2020, 194, 178-182.	1.7	3
20	Can echocardiography improve the prediction of thromboembolic risk in atrial fibrillation? Evidences and perspectives. Internal and Emergency Medicine, 2020, 15, 935-943.	2.0	8
21	Inferior vena cava agenesis in patients with lower limb deep vein thrombosis in the RIETE registry. When and why to suspect. International Journal of Cardiology, 2020, 305, 115-119.	1.7	16
22	Outcomes after venous thromboembolism in patients with gastric cancer: Analysis of the RIETE Registry. Vascular Medicine, 2020, 25, 210-217.	1,5	4
23	Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat?. Polish Archives of Internal Medicine, 2020, 131, 161-170.	0.4	4
24	Atrial fibrillation, cancer and echocardiography. Journal of Cardiovascular Echography, 2020, 30, 33.	0.4	5
25	Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: A cross-sectional study. International Journal of Cardiology, 2019, 274, 1-6.	1.7	32
26	Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies. Seminars in Thrombosis and Hemostasis, 2019, 45, 468-477.	2.7	19
27	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro) Tj ETQq1 1 0.78 2019, 45, 793-801.	4314 rgBT /C 2.7	Overlock 10 T 12
28	Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series. Journal of Thrombosis and Haemostasis, 2019, 17, 492-498.	3.8	1
29	Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis. Internal and Emergency Medicine, 2019, 14, 447-449.	2.0	5
30	Eculizumab in pregnancy: a narrative overview. Journal of Nephrology, 2019, 32, 17-25.	2.0	46
31	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. Internal and Emergency Medicine, 2019, 14, 21-38.	2.0	13
32	Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. Thrombosis Research, 2018, 164, 69-74.	1.7	35
33	Cytomegalovirus-Associated Splanchnic Vein Thrombosis in Immunocompetent Patients: Two Case Reports and Literature Review. Seminars in Thrombosis and Hemostasis, 2018, 44, 298-303.	2.7	3
34	Prophylaxis of venous thromboembolism in Internal Medicine Units: the RAMs issue. Internal and Emergency Medicine, 2018, 13, 463-465.	2.0	2
35	Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 928-935.	1.7	3
36	Left ventricular diastolic abnormalities other than valvular heart disease in antiphospholipid syndrome: An echocardiographic study. International Journal of Cardiology, 2018, 271, 366-370.	1.7	17

#	Article	IF	Citations
37	The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies. Atherosclerosis, 2018, 278, 60-65.	0.8	33
38	Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism. American Journal of Medicine, 2018, 131, 1095-1103.	1.5	41
39	Impact of cardiovascular and immunologic variables on subclinical carotid atherosclerosis in subjects with anti-phospholipid antibodies. Data in Brief, 2018, 19, 1799-1803.	1.0	7
40	The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. Saudi Journal of Gastroenterology, 2018, 24, 25.	1.1	15
41	Italian intersociety consensus on DOAC use in internal medicine. Internal and Emergency Medicine, 2017, 12, 387-406.	2.0	44
42	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. Oncologist, 2017, 22, 601-608.	3.7	108
43	Inferior Vena Cava Agenesis and Deep Vein Thrombosis in the Young: A Review of the Literature and Local Experience. Seminars in Thrombosis and Hemostasis, 2017, 43, 827-835.	2.7	18
44	The role of cardiovascular ultrasound in diagnosis and management of pulmonary embolism. Future Cardiology, 2017, 13, 465-477.	1.2	2
45	The "very rare―unusual sites venous thromboses. Internal and Emergency Medicine, 2017, 12, 745-747.	2.0	0
46	Cyclic supplementation of 5-MTHF is effective for the correction of hyperhomocysteinemia. Nutrition Research, 2015, 35, 489-495.	2.9	8
47	Oral Anticoagulant Drugs and the Risk of Osteoporosis: New Anticoagulants Better than Old?. Seminars in Thrombosis and Hemostasis, 2015, 41, 382-388.	2.7	54
48	Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases. Blood Transfusion, 2015, 13, 328-32.	0.4	3
49	Ensuring medication adherence with direct oral anticoagulant drugs. Thrombosis Research, 2014, 133, 699-704.	1.7	39
50	HELLP syndrome and its relation with the antiphospholipid syndrome. Blood Transfusion, 2014, 12, 114-8.	0.4	14
51	Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis. Blood Transfusion, 2014, 12 Suppl 1, s337-42.	0.4	12
52	Current and evolving features in the clinical management of haemophilia. Blood Transfusion, 2014, 12 Suppl 3, s554-62.	0.4	4
53	The Infectious Burden in Atherothrombosis. Seminars in Thrombosis and Hemostasis, 2012, 38, 515-523.	2.7	39
54	Acquired Inhibitors of Coagulation Factors: Part Iâ€"Acquired Hemophilia A. Seminars in Thrombosis and Hemostasis, 2012, 38, 433-446.	2.7	86

#	Article	IF	CITATION
55	Longâ€term outcomes of patients with cerebral vein thrombosis: a multicenter study. Journal of Thrombosis and Haemostasis, 2012, 10, 1297-1302.	3.8	129
56	Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Internal and Emergency Medicine, 2012, 7, 9-13.	2.0	32
57	Bleeding and Thrombosis in Multiple Myeloma and Related Plasma Cell Disorders. Seminars in Thrombosis and Hemostasis, 2011, 37, 929-945.	2.7	57
58	The Challenge of Diagnosing Pulmonary Embolism in Children, Pregnant Women, and Elderly Patients: A Descriptive Review of the Literature. Seminars in Thrombosis and Hemostasis, 2011, 37, 908-917.	2.7	4
59	Preventing Postsurgical Venous Thromboembolism: Pharmacological Approaches. Seminars in Thrombosis and Hemostasis, 2011, 37, 252-266.	2.7	38
60	Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: A Review of the Literature. Seminars in Thrombosis and Hemostasis, 2011, 37, 267-274.	2.7	44
61	The "antiphospholipid triangle―in an asymptomatic patient: a case report. Internal and Emergency Medicine, 2010, 5, 457-458.	2.0	1
62	Cardiovascular risk factors and outcome in patients with retinal vein occlusion. Journal of Thrombosis and Thrombolysis, 2010, 30, 16-22.	2.1	65
63	Treatment of hemophilia: a review of current advances and ongoing issues. Journal of Blood Medicine, 2010, 1, 183.	1.7	89
64	Mesoglycan: Clinical Evidences for Use in Vascular Diseases. International Journal of Vascular Medicine, 2010, 2010, 1-8.	1.0	23
65	Acquired Haemophilia A in the Elderly: Case Reports. Current Gerontology and Geriatrics Research, 2010, 2010, 1-5.	1.6	19
66	High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World Journal of Gastroenterology, 2010, 16, 6119.	3.3	57
67	Cardiovascular events in patients with antiphospholipid antibodies: Strategies of prevention. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 217-223.	2.6	10
68	Inherited Thrombophilia: Implications for Prevention and Treatment of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2009, 35, 683-694.	2.7	75
69	Budd-Chiari syndrome in a paroxysmal nocturnal hemoglobinuria patient with previous cerebral venous thrombosis. Internal and Emergency Medicine, 2009, 4, 75-77.	2.0	7